Evidence map›Paper›PMID 39478146›Full record

ArticleCommunications biology2024

A spatial hierarchical network learning framework for drug repositioning allowing interpretation from macro to micro scale.

Zhonghao Ren, Xiangxiang Zeng, Yizhen Lao, Heping Zheng, Zhuhong You, Hongxin Xiang, Quan Zou

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhonghao RenCollege of Computer Science and Electronic Engineering, Hunan University, Changsha, China.ORCID 0000-0002-1614-8988
Xiangxiang ZengCollege of Computer Science and Electronic Engineering, Hunan University, Changsha, China.ORCID 0000-0003-1081-7658
Yizhen LaoCollege of Computer Science and Electronic Engineering, Hunan University, Changsha, China.ORCID 0000-0002-6284-1724
Heping ZhengCollege of Biology, Department of Molecular Medicine, Hunan University, Changsha, China.ORCID 0000-0002-6961-4938
Zhuhong YouSchool of Computer Science, Northwestern Polytechnical University, Xi'an, China.
Hongxin XiangCollege of Computer Science and Electronic Engineering, Hunan University, Changsha, China.ORCID 0000-0001-8345-8735
Quan ZouInstitute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu, China. zouquan@nclab.net.ORCID 0000-0001-6406-1142

Funding

National Natural Science Foundation of China (National Science Foundation of China) 62131004National Natural Science Foundation of China (National Science Foundation of China) 62250028
6 · The paper itself

Abstract

Biomedical network learning offers fresh prospects for expediting drug repositioning. However, traditional network architectures struggle to quantify the relationship between micro-scale drug spatial structures and corresponding macro-scale biomedical networks, limiting their ability to capture key pharmacological properties and complex biomedical information crucial for drug screening and therapeutic discovery. Moreover, challenges such as difficulty in capturing long-range dependencies hinder current network-based approaches. To address these limitations, we introduce the Spatial Hierarchical Network, modeling molecular 3D structures and biological associations into a unified network. We propose an end-to-end framework, SpHN-VDA, integrating spatial hierarchical information through triple attention mechanisms to enhance machine understanding of molecular functionality and improve the accuracy of virus-drug association identification. SpHN-VDA outperforms leading models across three datasets, particularly excelling in out-of-distribution and cold-start scenarios. It also exhibits enhanced robustness against data perturbation, ranging from 20% to 40%. It accurately identifies critical motifs for binding sites, even without protein residue annotations. Leveraging reliability of SpHN-VDA, we have identified 25 potential candidate drugs through gene expression analysis and CMap. Molecular docking experiments with the SARS-CoV-2 spike protein further corroborate the predictions. This research highlights the broad potential of SpHN-VDA to enhance drug repositioning and identify effective treatments for various diseases.

Indexed as

Drug RepositioningSARS-CoV-2Antiviral AgentsCOVID-19COVID-19 Drug TreatmentHumansMachine LearningAntiviral Agents

Identifiers

PMID39478146
PMCPMC11525566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.